FDC · FDC Ltd · Biotechnology & Drugs
FDC · FDC Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
17.4% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹668 Cr
Revenue YoY
PAT YoY
+9.2%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
2.3
P/S (TTM)
Not available from data source
Sector P/E
Not available from data source
Dividend yield
+2.7%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| FDC (this stock) | 19.6 | 2.3 | +13.4% | +11.8% | 0.01 | +2.7% |
| Sun Pharmaceutical Industries | 36.6 | 5.3 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
| Divi's Laboratories * | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 75.8 | 20 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
* Net margin, ROE, D/E and dividend yield for these companies come from RedixFi fundamentals; the data vendor had no values for them.
Promoter
stable
FII
falling 1q
MF
6.25% (+0.02pp)
stable
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 24 Jun 2026 | NANDAN MOHAN CHANDAVARKAR | SELL | 50,30,086 | ₹0 |
| 24 Jun 2026 | NANDAN MOHAN CHANDAVARKAR (In the capacity of Trustee Mohan Anand Chandavarkar Trust) | BUY | 26,70,316 | ₹0 |
| 24 Jun 2026 | NANDAN MOHAN CHANDAVARKAR (In the capacity of Trustee Sandhya Mohan Chandavarkar Trust) | BUY | 23,59,770 | ₹0 |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedFDC Limited's annual report for FY2025-26 highlights the company's commitment to delivering affordable, high-quality healthcare solutions globally. The report emphasizes FDC's strong foundation in pharmaceutical manufacturing, with a focus on expanding its international presence and enhancing research and development capabilities. The company has reinforced its governance structure, prioritizing transparency, integrity, and ethical business practices. Additionally, FDC has strengthened its environmental, social, and governance (ESG) initiatives, including improved workplace safety and sustainability practices.
- Commitment to delivering affordable, high-quality healthcare solutions globally
- Focus on expanding international presence and enhancing R&D capabilities
- Reinforced governance structure with emphasis on transparency and ethical practices
- Strengthened ESG initiatives including workplace safety and sustainability
Key takeaway: FDC Limited is reinforcing its position as a global pharmaceutical leader through strategic expansion, enhanced R&D, and robust governance practices.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
FDC Limited has undisputed statutory dues including GST, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess that were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has contingent liabilities including disputed tax matters (income tax, GST, sales tax), guarantees given by banks for performance obligations, letters of credit issued by bankers, estimated duty payable on export obligations, and a demand from the National Pharmaceutical Pricing Authority for alleged overcharging in formulations under the Drugs (Prices Control) Order, 1995.
Earlier (1-3 years ago)
The company received notices of demand (including interest) from the National Pharmaceutical Pricing Authority, Government of India, on account of alleged overcharging in respect of certain formulations under the Drugs (Prices Control) Order, 1995.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
FDC Limited has outstanding statutory dues under dispute for various tax periods, including Income Tax, Sales Tax, and GST, with amounts in dispute ranging across multiple years and pending before various tax authorities.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
1.32% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).